# XORTX THERAPEUTICS INC (XRTX)

> Institutional ownership reported to the SEC as of Q2 2026, from Form 13F filings. Source: https://holderbook.com/stocks/XRTX/

- Reporting holders: 6
- Reported value: $145.3K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [CITADEL ADVISORS LLC](https://holderbook.com/funds/1423053-citadel-advisors-llc/) | $104.9K | 46,232 | 0.0% | 1 |
| [StoneX Group Inc.](https://holderbook.com/funds/913760-stonex-group-inc/) | $37.9K | 16,369 | 0.0% | 1 |
| [ROYAL BANK OF CANADA](https://holderbook.com/funds/1000275-royal-bank-of-canada/) | $2.0K | 732 | 0.0% | 1 |
| [NATIONAL BANK OF CANADA /FI/](https://holderbook.com/funds/926171-national-bank-of-canada-fi/) | $329 | 162 | 0.0% | 1 |
| [Clearstead Advisors, LLC](https://holderbook.com/funds/842775-clearstead-advisors-llc/) | $120 | 55 | 0.0% | 2 |
| [TD Waterhouse Canada Inc.](https://holderbook.com/funds/1999606-td-waterhouse-canada-inc/) | $19 | 9 | 0.0% | 1 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q2 2026 | 6 | $145.3K |
| Q1 2026 | 3 | $6.2K |
| Q4 2025 | 6 | $123.6K |
| Q3 2025 | 5 | $81.5K |
| Q2 2025 | 6 | $61.2K |
| Q1 2025 | 2 | $416 |
| Q4 2024 | 6 | $324.4K |
| Q3 2024 | 7 | $42.3K |
| Q2 2024 | 5 | $30.4K |
| Q1 2024 | 4 | $67.2K |
| Q4 2023 | 4 | $160.6M |
| Q3 2023 | 4 | $9.8K |